{
    "clinical_study": {
        "@rank": "124417", 
        "arm_group": {
            "arm_group_label": "Sym004", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This is a Phase 1, open-label, dose-escalation trial to assess the safety and tolerability\n      of Sym004, administered weekly or biweekly as monotherapy in Japanese subjects with advanced\n      solid tumors."
        }, 
        "brief_title": "Japanese Phase 1 Trial of Sym004 in Solid Tumors", 
        "completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Solid Tumors", 
        "condition_browse": {
            "mesh_term": "Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Japanese male or female subjects aged greater than or equal to 20 years at the time\n             of informed consent signature\n\n          -  Histologically or cytologically confirmed cancer\n\n          -  Refractory  or  recurrent  advanced  late  stage  solid tumors  without  available\n             therapeutic  options  which  are likely  to  provide  patient  benefit  (failure\n             and/or intolerance to standard anti-cancer therapy)\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n\n          -  Life expectancy of at least 3 months\n\n          -  Written  informed  consent  given  before  any  trial-related activities are carried\n             out\n\n          -  Other protocol defined inclusion criteria could apply\n\n        Exclusion Criteria:\n\n          -  Subjects with symptomatic brain metastases\n\n          -  Subjects who received total resection or irradiation of the target lesion\n\n          -  Received any  of  the  following  medications within 4 weeks  before  the  first\n             administration  of  Sym004  at Week 1: cytotoxic  or  cytostatic  anti-cancer\n             therapy, antibody  therapy,  tyrosine  kinase  inhibitors,  and  any investigational\n             agent\n\n          -  Received vaccine therapy  as  anticancer  treatment within 12 weeks  before  the\n             first  administration  of Sym004 at Week 1\n\n          -  Diarrhea of greater than Grade 1 according to  National Cancer Institute-Common\n             Terminology  Criteria  for  Adverse Events (NCI-CTCAE) version 4.03 (v4.03)\n\n          -  Skin  manifestation of greater than Grade 1  according  to  NCI-CTCAE (v4.03)\n\n          -  Magnesium of less than 0.9 milligram per deciliter (mg/dL)\n\n          -  Abnormal organ or bone marrow function as defined in the protocol\n\n          -  Received immunosuppressive agents (including systemic corticosteroids used at doses\n             above 20 milligram per day (mg/day) of prednisolone or equivalent) within 4 weeks\n             before the first administration of Sym004 at Week 1\n\n          -  Active severe infection, any other concurrent disease or  medical  conditions  that\n             are  deemed  to  interfere  with the conduct of the trial as judged by the\n             Investigator\n\n          -  Known human immunodeficiency virus  (HIV) positive, active Hepatitis B or C, or\n             uncontrolled allergic conditions or allergy to Sym004 or its components\n\n          -  Clinically  significant  cardiac disease or concurrent,  uncontrolled  medical\n             condition\n\n          -  Known  previous  Grade 3 to 4  infusion-related reactions, according  to  NCI-CTCAE\n             (v4.03),  with chimeric monoclonal antibodies\n\n          -  Other protocol defined exclusion criteria could apply"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "54", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 27, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01955473", 
            "org_study_id": "EMR 200637-001"
        }, 
        "intervention": {
            "arm_group_label": "Sym004", 
            "description": "Part-A (dose-escalation): Sym004 will be administered intravenously either weekly at 6 to 12 milligram per kilogram (mg/kg) or biweekly at 18 mg/kg from Week 1 until unacceptable toxicity, disease progression, or consent withdrawal. Part-B (dose-expansion): After the maximum tolerated dose (MTD) is determined in Part-A, up to 30 additional subjects will continue to receive treatment in Part-B.", 
            "intervention_name": "Sym004", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Solid tumors", 
            "Sym004", 
            "Phase 1"
        ], 
        "lastchanged_date": "February 4, 2014", 
        "location": {
            "contact": {
                "email": "service@merckgroup.com", 
                "phone": "+49-6151-72-5200"
            }, 
            "facility": {
                "address": {
                    "city": "Darmstadt", 
                    "country": "Germany"
                }, 
                "name": "Please contact the Merck KGaA Communication Center located in"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Japanese Phase I Open-label Dose-escalation Trial of Sym004 Administered as Monotherapy in Japanese Subjects With Advanced Solid Tumors", 
        "overall_contact": {
            "email": "service@merckgroup.com", 
            "last_name": "Merck KGaA Communication Center", 
            "phone": "+49 6151 72 5200"
        }, 
        "overall_official": {
            "affiliation": "Merck Serono Co., Ltd., Japan", 
            "last_name": "Medical Responsible", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Dose Limiting Toxicity as determined in Part-A", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Week 4"
            }, 
            {
                "measure": "Number of subjects with Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 4 weeks after the last Sym004 administration"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01955473"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Pharmacokinetic profile of Sym004:  Area under curve (AUC), Half-life (t1/2 ), Clearance (CL), Volume of distribution at the elimination phase (Vz ), Maximum concentration (Cmax ), Trough concentration (Ctrough), Time to reach Cmax (tmax )", 
                "safety_issue": "No", 
                "time_frame": "Up to 8 weeks after the last Sym004 administration"
            }, 
            {
                "measure": "Best overall response rate", 
                "safety_issue": "No", 
                "time_frame": "Week 7 and thereafter every 6 weeks, up to 4 weeks after the last Sym004 administration"
            }, 
            {
                "measure": "Duration of overall response", 
                "safety_issue": "No", 
                "time_frame": "Week 7 and thereafter every 6 weeks until the first date of objectively documented recurrent or progressive disease, up to 4 weeks after the last Sym004 administration"
            }, 
            {
                "measure": "Disease control rate", 
                "safety_issue": "No", 
                "time_frame": "Week 7 and thereafter every 6 weeks, up to 4 weeks after the last Sym004 administration"
            }, 
            {
                "measure": "Duration of disease control", 
                "safety_issue": "No", 
                "time_frame": "Week 7 and thereafter every 6 weeks until the first date of objectively documented recurrent or progressive disease, up to 4 weeks after the last Sym004 administration"
            }, 
            {
                "measure": "Time to progression", 
                "safety_issue": "No", 
                "time_frame": "Time from enrollment until the date of  objectively documented disease progression, up to 4 weeks after the last Sym004 administration"
            }, 
            {
                "measure": "Progression-free survival time", 
                "safety_issue": "No", 
                "time_frame": "Time from enrollment until the date of objectively documented disease progression or death, up to 4 weeks after the last Sym004 administration"
            }, 
            {
                "measure": "Change from Baseline in anti-drug antibody (ADA) titer at Weeks 1 and 5", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Weeks 1 and 5"
            }, 
            {
                "measure": "Epidermal  growth factor receptor levels in skin tissues", 
                "safety_issue": "No", 
                "time_frame": "Weeks 1 and 5"
            }
        ], 
        "source": "Merck KGaA", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck KGaA", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}